Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial

References

• Piccaluga PP, Agostinelli C, Gazzola A, et al. Pathobiology of Hodgkin lymphoma. Adv Hematol. 2011;2011:1–18.
   Google Scholar
• National Institutes of Health. Cancer stat facts: Hodgkin lymphoma 2022 [cited 2022 Aug 9]. Available from: https://seer.cancer.gov/statfacts/html/hodg.html
   Google Scholar
• Shanbhag S, Ambinder RF. Hodgkin lymphoma: a review and update on recent progress. CA Cancer J Clin. 2018;68(2):116–132.
   PubMed Web of Science ®Google Scholar
• Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021. CA A Cancer J Clin. 2021;71(1):7–33.
   PubMed Web of Science ®Google Scholar
• Deutsch YE, Tadmor T, Podack ER, et al. CD30: an important new target in hematologic malignancies. Leuk Lymphoma. 2011;52(9):1641–1654.
   PubMed Web of Science ®Google Scholar
• Kuppers R, Hansmann ML. The Hodgkin and reed/Sternberg cell. Int J Biochem Cell Biol. 2005;37(3):511–517.
   PubMed Web of Science ®Google Scholar
• Canellos GP, Anderson JR, Propert KJ, et al. Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med. 1992;327(21):1478–1484.
   PubMed Web of Science ®Google Scholar
• Ansell SM, Radford J, Connors JM, et al. Overall survival with brentuximab vedotin in stage III or IV Hodgkin’s lymphoma. N Engl J Med. 2022;387(4):310–320.
   PubMed Web of Science ®Google Scholar
• Borchmann P, Goergen H, Kobe C, et al. PET-guided treatment in patients with advanced-stage Hodgkin’s lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the German Hodgkin Study Group. Lancet. 2017;390(10114):2790–2802.
   PubMed Web of Science ®Google Scholar
• Casasnovas RO, Bouabdallah R, Brice P, et al. PET-adapted treatment for newly diagnosed advanced Hodgkin lymphoma (AHL2011): a randomised, multicentre, non-inferiority, phase 3 study. Lancet Oncol. 2019;20(2):202–215.
   PubMed Web of Science ®Google Scholar
• Gallamini A, Tarella C, Viviani S, et al. Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography/computed tomography scan after two ABVD cycles: long-term results of the GITIL/FIL HD 0607 trial. J Clin Oncol. 2018;36(5):454–462.
   PubMed Web of Science ®Google Scholar
• Johnson P, Federico M, Kirkwood A, et al. Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma. N Engl J Med. 2016;374(25):2419–2429.
   PubMed Web of Science ®Google Scholar
• Kreissl S, Goergen H, Buehnen I, et al. PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021;8(6):e398–e409.
   PubMed Web of Science ®Google Scholar
• Ricardi U, Levis M, Evangelista A, et al. Role of radiotherapy to bulky sites of advanced Hodgkin lymphoma treated with ABVD: final results of FIL HD0801 trial. Blood Adv. 2021;5(21):4504–4514.
   PubMedGoogle Scholar
• Stephens DM, Li H, Schoder H, et al. Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III/IV Hodgkin lymphoma. Blood. 2019;134(15):1238–1246.
   PubMed Web of Science ®Google Scholar
• National Comprehensive Cancer Network. Hodgkin lymphoma (Version 1.2022) 2021 [cited 2021 Nov 29]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/hodgkins.pdf
   Google Scholar
• Allen PB, Gordon LI. Frontline therapy for classical Hodgkin lymphoma by stage and prognostic factors. Clin Med Insights Oncol. 2017;11:117955491773107.
   Web of Science ®Google Scholar
• Ansell SM. Hodgkin lymphoma: 2018 update on diagnosis, risk-stratification, and management. Am J Hematol. 2018;93(5):704–715.
   PubMed Web of Science ®Google Scholar
• Relecom A, Federico M, Connors JM, et al. Resources-stratified guidelines for classical Hodgkin lymphoma. Int J Environ Res Public Health. 2020;17(5).
   PubMed Web of Science ®Google Scholar
• Bloudek B, Wirtz HS, Hepp Z, et al. Oncology simulation model: a comprehensive and innovative approach to estimate and project prevalence and survival in oncology. CLEP. 2022;14:1375–1386.
   Google Scholar
• Gallicchio L, Devasia TP, Tonorezos E, et al. Estimation of the number of individuals living with metastatic cancer in the United States. J Natl Cancer Inst. 2022;114(11):1476–1483.
   PubMedGoogle Scholar
• Advani RH, Moskowitz AJ, Bartlett NL, et al. Brentuximab vedotin in combination with nivolumab in relapsed or refractory Hodgkin lymphoma: 3-year study results. Blood. 2021;138(6):427–438.
   PubMed Web of Science ®Google Scholar
• Armand P, Engert A, Younes A, et al. Nivolumab for relapsed/refractory classic Hodgkin lymphoma after failure of autologous hematopoietic cell transplantation: extended follow-up of the multicohort single-arm phase II CheckMate 205 trial. J Clin Oncol. 2018;36(14):1428–1439.
   PubMed Web of Science ®Google Scholar
• Casadei B, Argnani L, Morigi A, et al. Effectiveness of chemotherapy after anti-PD-1 blockade failure for relapsed and refractory Hodgkin lymphoma. Cancer Med. 2020;9(21):7830–7836.
   PubMed Web of Science ®Google Scholar
• Chen R, Gopal AK, Smith SE, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128(12):1562–1566.
   PubMed Web of Science ®Google Scholar
• Chen R, Zinzani PL, Lee HJ, et al. Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087. Blood. 2019;134(14):1144–1153.
   PubMed Web of Science ®Google Scholar
• Herrera AF, Moskowitz AJ, Bartlett NL, et al. Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2018;131(11):1183–1194.
   PubMed Web of Science ®Google Scholar
• Kersten MJ, Driessen J, Zijlstra JM, et al. Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC transplant BRaVE study. Haematologica. 2021;106(4):1129–1137.
   PubMed Web of Science ®Google Scholar
• Kuruvilla J, Ramchandren R, Santoro A, et al. Pembrolizumab versus brentuximab vedotin in relapsed or refractory classical Hodgkin lymphoma (KEYNOTE-204): an interim analysis of a multicentre, randomised, open-label, phase 3 study. Lancet Oncol. 2021;22(4):512–524.
   PubMedGoogle Scholar
• LaCasce AS, Bociek RG, Sawas A, et al. Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma. Blood. 2018;132(1):40–48.
   PubMed Web of Science ®Google Scholar
• Moskowitz CH, Nademanee A, Masszi T, et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin’s lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2015;385(9980):1853–1862.
   PubMed Web of Science ®Google Scholar
• Santoro A, Mazza R, Pulsoni A, et al. Five-year results of the BEGEV salvage regimen in relapsed/refractory classical Hodgkin lymphoma. Blood Adv. 2020;4(1):136–140.
   PubMed Web of Science ®Google Scholar
• Hapgood G, Zheng Y, Sehn LH, et al. Evaluation of the risk of relapse in classical Hodgkin lymphoma at event-free survival time points and survival comparison with the general population in British Columbia. J Clin Oncol. 2016;34(21):2493–2500.
   PubMed Web of Science ®Google Scholar
• Bonafede M, Richhariya A, Cai Q, et al. Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies. J Med Econ. 2017;20(12):1244–1251.
   PubMed Web of Science ®Google Scholar
• André MPE, Carde P, Viviani S, et al. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: a pooled analysis of four randomized trials. Cancer Med. 2020;9(18):6565–6575.
   PubMed Web of Science ®Google Scholar
• Evens AM, Yu KS, Liu N, et al. Classic Hodgkin lymphoma: real-world observations from physicians, patients, and caregivers on the disease and its treatment (CONNECT): physician frontline treatment preferences for stage III or IV classic Hodgkin lymphoma. Pan Pacific Lymphoma Conference; 2022 Jul 18–22; Koloa, HI.
   Google Scholar
• Flora DR, Parsons SK, Liu N, et al. Classic Hodgkin lymphoma: real-world observations from physicians, patients, and caregivers on the disease and its treatment (CONNECT)—a cross-sectional survey of patients with stage III or IV classic Hodgkin lymphoma compared by age. Pan Pacific Lymphoma Conference; 2022 Jul 18–22; Koloa, HI.
   Google Scholar